{"id":542613,"date":"2021-05-10T23:10:02","date_gmt":"2021-05-10T23:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542613"},"modified":"2021-05-10T23:10:02","modified_gmt":"2021-05-10T23:10:02","slug":"frontotemporal-dementia-ftd-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/frontotemporal-dementia-ftd-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_542613.html","title":{"rendered":"Frontotemporal Dementia (FTD) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight"},"content":{"rendered":"
\"Frontotemporal<\/a><\/p>\n
\n
DelveInsight Busines Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ” Frontotemporal Dementia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Frontotemporal Dementia, historical and forecasted epidemiology as well as the Frontotemporal Dementia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Frontotemporal Dementia (FTD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/p>\n

DelveInsight’s “Frontotemporal Dementia (FTD) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the  Frontotemporal Dementia (FTD), historical and forecasted epidemiology as well as the  Frontotemporal Dementia (FTD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    As per the study the prevalence of FTD between the ages of 45–65 years ranged from 15 to 22 per 100,000 people, with incidence estimates ranging from 2.7 to 4.1 per 100,000 members in the same age range.<\/p>\n<\/li>\n

  2. \n

    As per the National Organization for Rare Disorder 2019, Frontotemporal degeneration is the second most common form of dementia in people under the age of 65 after Alzheimer’s disease. The mean age of onset is usually given at the late 50s, with an age range of 20–80. However, onset before 40 or after 75 is less common.<\/p>\n<\/li>\n

  3. \n

    As per Chiadikaobi U Onyike et al. 2013, Frontotemporal dementia, a heterogeneous neurodegenerative disorder, is a common cause of young onset dementia. The estimated point prevalence was 15–22 per 100,000 and Prevalence 2.7–4.1 per 100,000. Some 25% are late-life onset cases.<\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1.  Frontotemporal Dementia (FTD) market report covers a descriptive overview and comprehensive insight of the  Frontotemporal Dementia (FTD) epidemiology and  Frontotemporal Dementia (FTD) market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2.  Frontotemporal Dementia (FTD) market report provides insights on the current and emerging therapies.<\/p>\n

    3.  Frontotemporal Dementia (FTD) market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

    4. The  Frontotemporal Dementia (FTD) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the  Frontotemporal Dementia (FTD) market.<\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/frontotemporal-dementia-market<\/span><\/a><\/strong><\/p>\n

    Frontotemporal Dementia (FTD): Overview<\/strong><\/p>\n

    Frontotemporal dementia (FTD) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain areas. In this disorder, portions of these lobes shrink (atrophy). The degeneration of the frontotemporal lobe is primarily triggered due to proteins involvement TDP43 and tau, which directly outbreaks the damage on the temporal and frontal lobes of the brain.<\/p>\n

    The key player involved in Frontotemporal Dementia (FTD) market:<\/strong><\/a><\/p>\n

      \n
    1. \n

      TauRx Therapeutics<\/p>\n<\/li>\n

    2. \n

      Alector<\/p>\n<\/li>\n

    3. \n

      Neurimmune\/ Biogen<\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Frontotemporal Dementia (FTD) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drugs covered<\/strong><\/p>\n

        \n
      1. \n

        LMTX<\/p>\n<\/li>\n

      2. \n

        AL001<\/p>\n<\/li>\n

      3. \n

        NI205<\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/frontotemporal-dementia-market<\/a><\/span><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/p>\n

        2. Executive Summary<\/p>\n

        3. SWOT analysis<\/p>\n

        4.  Frontotemporal Dementia (FTD) Patient Share (%) Overview at a Glance<\/p>\n

        5.  Frontotemporal Dementia (FTD) Market Overview at a Glance<\/p>\n

        6.  Frontotemporal Dementia (FTD) Disease Background and Overview<\/p>\n

        7.  Frontotemporal Dementia (FTD) Epidemiology and Patient Population<\/p>\n

        8. Country-Specific Patient Population of  Frontotemporal Dementia (FTD)<\/p>\n

        9.  Frontotemporal Dementia (FTD) Current Treatment and Medical Practices<\/p>\n

        10. Unmet Needs<\/p>\n

        11.  Frontotemporal Dementia (FTD) Emerging Therapies<\/p>\n

        12.  Frontotemporal Dementia (FTD) Market Outlook<\/p>\n

        13. Country-Wise  Frontotemporal Dementia (FTD) Market Analysis (2017–2030)<\/p>\n

        14. Market Access and Reimbursement of Therapies<\/p>\n

        15. Market drivers<\/p>\n

        16. Market barriers<\/p>\n

        17. Appendix<\/p>\n

        18.  Frontotemporal Dementia (FTD) Report Methodology<\/p>\n

        19. DelveInsight Capabilities<\/p>\n

        20. Disclaimer<\/p>\n

        21. About DelveInsight<\/p>\n

        Related Reports:<\/strong><\/p>\n

        Frontotemporal Dementia (FTD)- Pipeline Insights, 2021<\/strong><\/p>\n

        ” Frontotemporal Dementia (FTD) Pipeline Insight, 2021″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the  Frontotemporal Dementia (FTD) market. A detailed picture of the  Frontotemporal Dementia (FTD) pipeline landscape is provided, which includes the disease overview and  Frontotemporal Dementia (FTD) treatment guidelines.<\/p>\n

        Frontotemporal Dementia (FTD)- Epidemiology Forecast 2030<\/strong><\/p>\n

        DelveInsight’s ‘ Frontotemporal Dementia (FTD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted  Frontotemporal Dementia (FTD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Busines Research LLP DelveInsight’s ” Frontotemporal Dementia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Frontotemporal Dementia, historical and forecasted epidemiology as well as the Frontotemporal Dementia market trends in the United States, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542613","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542613"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542613\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}